Table 1.
Baseline patient demographics and characteristics
| Study 1 | Study 2 | Study 3 | Total | |
|---|---|---|---|---|
| Patients | 42 | 39 | 59 | 140 |
| Observations | 204 | 531 | 359 | 1094 |
| Sex, %male/%female | 60/40 | 72/28 | 78/22 | 66/34 |
| Age, years | 65.5 (56–71) | 68 (61–74.5) | 68 (60.75–75) | 67 (59–74) |
| Weight, kg | 80 (64–90) | 80 (66–98.5) | 80 (70.75–93) | 80 (69–93) |
| Serum creatinine, μmol/L | 90 (70–153) | 83 (66–146.5) | 101 (76.75–158) | 97 (69–156) |
| eGFR, mL/min/1.73 m2 | 58.5 (31.75–101.75) | 67 (39–93) | 56.5 (37.75–93.75) | 59 (37–96) |
| Albumin, g/L | 25 (22-29) | 23 (18.5–26) | 24 (19–27) | 25 (20–28) |
| SOFA score | 12.5 (9–15.75) | 9 (5–13.5) | 10 (8–12) | 10 (8–13) |
| CVVH, % | 12 | 0 | 10 | 8 |
Data are expressed in median (interquartile range)
CVVH continuous veno-venous hemofiltration, eGFR estimated glomerular filtration rate calculated using the MDRD equation [20], SOFA Sequential Organ Failure Assessment